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Abstract
It has been a decade since the introduction of SH2 profiling, a modular domain-based molecular diagnostics tool. This review covers the original
concept of SH2 profiling, different analytical platforms, and their applications, from the detailed analysis of single proteins to broad screening in
translational research. Illustrated by practical examples, we discuss the uniqueness and advantages of the approach as well as its limitations and
challenges. We provide guidance for basic researchers and oncologists who may consider SH2 profiling in their respective cancer research, especially
for those focusing on tyrosine phosphoproteomics. SH2 profiling can serve as an alternative phosphoproteomics tool to dissect aberrant tyrosine
kinase pathways responsible for individual malignancies, with the goal of facilitating personalized diagnostics for the treatment of cancer.
Keywords: cancer, tyrosine phosphorylation, phosphoproteomics, SH2 domain, SH2 profiling

Tyrosine Phosphoproteomics in
Cancer
The availability of $1,000 whole-genome
sequencing will soon fuel personalized
medicine for life-threatening human diseases such as cancer.1,2 It is widely
accepted that somatic gene alteration is
the primary determinant of cancer and
can serve as a predictive marker for drug
response and patient prognosis.3,4 Proteomics, the large-scale analysis of gene
products, has also caught the attention of
cancer researchers, with sensitive mass
spectrometry as the driving force for
large-scale protein profiling of tumors.5,6
To design an effective therapy tailored for
each cancer patient based on gene and
protein profiles, it is necessary to define
the critical proteins responsible for the
hallmarks of cancer, such as oncogenic
cell growth or resistance to apoptosis.7
An important goal of current research is
to exploit these proteins as targets for the
rational design of highly specific anticancer agents. However, an obvious problem
is that most tumors contain many oncogenic mutations involved in a number of
essential signaling pathways,8 and antagonizing all of them may provide no
advantage over traditional chemotherapy
in terms of adverse effects and toxicity.9
This is why imatinib, a highly successful,
rationally designed drug solely targeting
the BCR-ABL tyrosine kinase in chronic

myelogenous leukemia (CML), has been
received with great enthusiasm.10 Tyrosine kinase inhibitors (TKIs) have also
been successfully used in the treatment of
solid tumors, validating the concept of
targeting therapy and the importance of
tyrosine kinase pathways in human
cancer.11
Tyrosine kinase (TK) signaling pathways are effective targets due to their
role as membrane-localized upstream
regulators relevant to cancer progression.12 For instance, receptor tyrosine
kinases (RTKs) receive extracellular
stimuli and transduce the signal to multiple downstream pathways controlling
many important biological functions
such as cell proliferation, differentiation, and cell motility.13 Consequently,
tyrosine phosphorylation controlled by a
delicate balance between tyrosine
kinases and phosphatases plays an
important role in the regulation of many
hallmarks of cancer, including cell
growth, angiogenesis, invasion, and
metastasis.7 Aberrant tyrosine phosphorylation has been reported in many different solid tumors and hematological
malignancies.14,15 Because of the prominent role of TK signaling pathways in
cancer, a single TKI can have far-reaching
effects, providing impetus for the pursuit of effective targets within tyrosine
kinase pathways.16 Currently, a major

problem is that tumors often acquire
resistance to initial TKI therapy through
various mechanisms, including the gatekeeper mutation and activation of other
TKs, which has led to the development
of more potent second-generation multitarget TKIs.17,18 Design of sustainable
therapeutic strategies and molecular
diagnosis of TK pathways demands
comprehensive and versatile analytical
platforms to decipher phosphotyrosinedependent signaling networks in cancer
cells.
Mass spectrometry (MS) and sitespecific anti-phosphotyrosine antibodies
are frequently used for the analysis of
tyrosine phosphorylation in cancer.6,19
Due to the low abundance of tyrosine
phosphorylated proteins, enrichment is
essential prior to the analysis by MS.20 A
common strategy in which MS is preceded by the immunoaffinity enrichment of phosphopeptides introduced by
Rush et al.21 in 2005 has yielded a rich
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source of information on dysregulated
kinases and other signaling proteins in
many types of cancer. One disadvantage
of this approach is that relatively large
amounts of cells or tissue are required
for comprehensive phosphoproteome
analysis, limiting this approach especially for clinical applications where
only a small amount of cancer tissue is
available. Although the sensitivity of
MS is greatly improving, typically 100
to 500 mg of cancer tissues has been
used in recent phosphoproteomics studies.5,22,23 The requirement of highly specialized instrumentation not available in
every laboratory is another disadvantage
of MS. Furthermore, it is not always
obvious whether tyrosine phosphorylated peptides identified by MS are
in fact directly involved in signal transduction or how a pTyr site may affect
downstream signaling. As an alternative
to comprehensive MS analysis, antiphosphotyrosine antibodies directed
against previously defined sites of phosphorylation should offer unambiguous
profiling of phosphotyrosine-dependent
signaling. At present, a substantial
number of these site-specific antiphosphotyrosine antibodies are commercially available. However, considering
the large number of phosphorylation
sites identified in the proteomes of cancer cells, the current panel of antibodies
would appear to be insufficient. Moreover, a significant number of commercially available antibodies do not offer
sufficient specificity.24

Concept of SH2 Profiling
Given the limitations of common phosphoproteomics strategies, we developed
SH2 profiling as a complementary
approach for the characterization of the
global phosphorylation state.25-27 The key
components of our analytical platform
are Src Homology 2 (SH2) domains, naturally occurring protein interaction
domains that recognize specific phosphorylated tyrosine motifs.28 As an integral part of many important signaling
proteins, SH2 domains are by far the
most prevalent phosphotyrosine-binding
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module. There are ~120 different SH2
domains encoded in the human genome.29
With a size of approximately 100 amino
acids, SH2 domains adopt a characteristic
structure composed of a central antiparallel beta sheet flanked by 2 alpha helices.
Recognition of phosphotyrosine residues
is generally mediated by a conserved,
positively charged arginine residue buried in the binding pocket of the SH2
domain. The selectivity of binding to
tyrosine phosphorylated ligands is determined by a short stretch of amino acids
usually spanning 3 to 5 residues Cterminal to the phosphotyrosine. Additional specificity can be conferred by
N-terminal residues of ligands and a secondary binding site.30,31 In addition, it has
recently been shown that SH2 binding
can be negatively affected by local
sequence context such that neighboring
positions influence one another.32 Functionally, binding of the SH2 domains to
their ligands in the vicinity of the plasma
membrane couples the molecular switch
of tyrosine phosphorylation (on) or
dephosphorylation (off) to downstream
effectors. Designated as intracellular
“readers” of the state of tyrosine phosphorylation, SH2 domains play a key role
in the interpretation, processing, and
transduction of cellular signals.33 This
unique binding characteristic of SH2
domains thus confers specificity to signal
transduction and forms the conceptual
basis of SH2 profiling (Fig. 1A).
Using a battery of purified SH2
domains for in vitro binding assays, it is
possible to quantitatively assess the
presence of SH2 domain binding sites
(phosphotyrosine motifs) in analytes
(e.g., proteins, cell lysates, etc.). In this
system (SH2 profiling), a positive SH2
hit suggests that the corresponding SH2
domain containing protein, if expressed
in the cell, is involved in tyrosine phosphorylation-dependent protein-protein
interaction as part of a tyrosine kinase
pathway. Thus, SH2 profiling can provide functional TK pathway information
missed in phosphosite cataloguing, making SH2 profiling a unique and complementary approach to conventional
tyrosine phosphoproteomics (Fig. 1B).

For example, antibody microarray or
MS analysis can provide the phosphorylation state of tyrosines on a HER2/
ErbB2 receptor in a breast cancer sample, whereas SH2 profiling can show the
presence of binding sites for specific
SH2 domain–containing proteins on the
same receptor. Noteworthy, SH2 profiling assays are not restricted by previous
knowledge of phosphorylation sites (i.e.,
unbiased coverage of tyrosine phosphoproteome), and the sample requirement
is equivalent to that for phosphoantibody-based immunoblotting (i.e., lower
sample requirement than conventional
MS). On the other hand, in SH2 profiling, the actual identification of SH2
ligands requires subsequent antibody or
MS analysis. Taken together, SH2 profiling provides qualitatively different
information from conventional proteomics approaches. In view of the
importance of TK pathways in cancer,
we hypothesized that SH2 profiling
could serve as an important diagnostic
tool that can discern subclasses of
tumors based on global tyrosine phosphorylation state.25

Assay Platforms for SH2
Profiling
Modular protein interaction domains
have been widely used as tool in proteomics for various purposes such as
ligand screening, specificity determination, and domain-ligand interactome
analysis.34,35 Similar to antibodies, modular domains can be used in different
binding assay platforms defined by
immobilization and detection methods.
For example, purified SH2 domain proteins can be arrayed on a solid support
and incubated with fluorescently labeled
samples in solution (e.g., forward-phase
array36), or samples can be arrayed on
solid phase and incubated with labeled
SH2 domains in solution (e.g., reversephase array26). Alternatively, interaction
can be assessed with both samples and
SH2 domains in solution (e.g., fluorescence polarization32). We previously
observed that a reverse-phase format has
superior sensitivity over a forward-phase
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Figure 1. Concept and analytical platforms of SH2 profiling. (A) Diagrammatic view of tyrosine
kinase signaling state defined by SH2 binding sites. Many extracellular stimuli activate tyrosine
kinases, resulting in quantitative changes in tyrosine phosphorylated sites on cellular proteins.
These changes are “read” by specific pTyr-recognizing modules such as SH2 domains, to
propagate the signal to downstream effectors. These characteristics of SH2 domains form the
conceptual basis of SH2 profiling. Red circles represent tyrosine phosphorylated sites (P), and
different SH2 domains are distinguished by color. (B) Different analytical platforms of tyrosine
phosphoproteomics. Tyrosine phosphorylated peptides are detected by mass spectrometry (MS),
anti-phosphotyrosine antibodies (pTyr Ab), or SH2 domains (SH2). MS provides information on the
sequence and type of modification, pTyr Ab provides site-specific phosphorylation status, and SH2
detects activated, tyrosine phosphorylated SH2 domain binding sites. (C) SH2 profiling platforms.
In far-Western analysis, protein samples are separated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE), and replicate blots are separately probed with horseradish
peroxidase (HRP)–labeled SH2 domains. In rosette assay, samples are spotted on membrane, and
the binding assay is carried out in a 96-well plate. HRP-labeled SH2 domain probes are incubated
with multiple sample spots in a noncompetitive manner (single SH2 per well). In an oligonucleotidetagged multiplex (OTM) assay, a mixture of SH2 domains with domain-specific DNA tags are
incubated with a sample spot allowing for competitive binding (single sample per well). Signal is
detected either by chemiluminescence (far-Western and rosette) or real-time polymerase chain
reaction (OTM). Quantified values are used to classify samples, such as different cancer tissues,
based on SH2 binding preferences (SH2 profiles).

format for analyzing complex whole-cell
lysates.37 One possible explanation is that
SH2 domains may be partially inactivated during the immobilization procedures in forward-phase formats. We also
assume that in reverse phase, binding is
driven by the relatively high levels of
SH2 domain protein in solution. Whereas
in forward phase, the concentration of
pTyr proteins in lysate solution is
extremely low, so signal to noise is poor.
Over the past years, we have developed
several different analytical platforms for
SH2 profiling in the reverse-phase format
(Fig. 1C). All platforms are relatively

simple, low cost, and amenable to standard laboratories, although experimental
setup is a largely manual process in contrast with automated high-throughput
phosphoproteomics systems. Technical
details have been described in previous
publications.26,27,38-40
Quantitative Far-Western Analysis

Far-Western blotting is the original platform of SH2 profiling. Whole cellular
protein extracts are separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred to
membranes, and subsequently probed

M

with a panel of labeled SH2 domain proteins.25,39 Binding of a SH2 domain to
the membrane-immobilized proteins is
detected using chemiluminescence. The
quantitative SH2 binding profiles of different samples are assessed by apparent
molecular size and intensity of bands.
An advantage of far-Western over conventional pull-down assays is that interactions between a purified SH2 domain
and proteins on the membrane are direct,
whereas proteins detected in a SH2 pulldown assay may contain indirect binding partners. Using a cancer cell line
expressing various tyrosine mutants of
the PDGF receptor, we demonstrated the
specificity of SH2 domains, which is
improved when a labeled SH2 probe is
mixed with several unlabeled domains
(competitive binding25). However, we
do not usually perform competitive
assays, as various degrees of competition in binding may quench relevant signals especially when the concentration
of phosphoproteins is low.
Although SH2 profiling aims to quantitatively analyze many cancer samples
and SH2 domains in parallel, accurate
comparison of far-Western blotting
results from multiple experiments is challenging due to gel-to-gel and experimental variations. To overcome the issue, we
make multiple efforts, including the use
of a multigel apparatus, normalization by
internal controls, assay replication, and
gel band matching with reference blots.40
For example, pervanadate-treated cell
lysates and tyrosine phosphatase-treated
lysates can be used as positive and negative controls, respectively, to ensure SH2
probe activity and normalize signal intensity. Reprobing with an anti-pTyr antibody also allows for band matching and
quantification of replicate blots using
image analysis software. Consequently,
far-Western blots of multiple samples
with many SH2 probes can be compared
and used as the basis for bioinformatics
analysis.
Rosette Assay

Although far-Western blotting provides a
rich molecular signature based on SH2
binding, it is inherently low throughput
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and requires relatively large amounts of
sample, therefore precluding comprehensive SH2 profiling (>100 SH2 probes).
To address this problem, we developed a
reverse-phase dot-blotting assay platform
(rosette assay). In the rosette assay, nanogram amounts of whole cellular protein
extract are serially spotted on a membrane in register with the wells of a
96-well chamber apparatus, allowing
parallel probing of ~100 SH2 domains in
a single assay. The number of samples
analyzed is customizable up to about 100.
Since the essential reagents for the farWestern and rosette assays, including
labeled SH2 probes and detection system,
are identical, they can be coupled; the
rosette assay is used for SH2 library
screening using minimal amounts of
lysate, and subsequently positive hits are
confirmed and further analyzed by farWestern. Based on this strategy, a full
survey of SH2 interactions using only a
few hundred micrograms of lysate, without any phospho-enrichment process, is
feasible.26 The library screening result,
including positive and negative controls,
is digitally captured, quantified using
densitometry, and then further processed
by bioinformatic analysis.
Oligonucleotide-Tagged Multiplex
(OTM) Assay

The oligonucleotide-tagged multiplex
(OTM) assay is a distinctive reversephase assay from rosette. In the rosette
assay, a single SH2 domain is incubated
with multiple samples in each well (noncompetitive binding), whereas in OTM, a
mixture of SH2 domains differentially
tagged with DNA-oligonucleotides is
incubated with a single sample. This
enables multiplex competitive binding
(Fig. 1C). Biotinylated SH2 domains,
generated in bacteria using the BirA system, are complexed with biotinylated oligonucleotides via a streptavidin bridge.
Following incubation of the DNA-tagged
SH2 probes with a sample in a multiwell
plate, the bound probes are eluted
and quantified by real-time polymerase
chain reaction (PCR).27,38 Because it
incorporates multiplex SH2 binding and
PCR-based detection, OTM offers
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excellent sensitivity (low femtomole
amounts of a phosphopeptide) and low
sample requirement (10 µg of cell extract
to assess multiple domains). Currently,
efforts are under way to reduce the complexity of the quantification process
through absolute quantification of the
DNA tags by parallel high-throughput
sequencing.
Technical Considerations

Since SH2 profiling assays rely on
in vitro purified proteins, activity of
probes can affect the quality and coverage
of the system. We and others have
observed that 30% to 40% of SH2
domains purified from bacteria are somewhat or completely insoluble, requiring
refolding or alternative expression systems.26,36 These domains tend to be inactive when assessed using a phosphatase
inhibitor–treated positive control, presumably due to misfolding or degradation
in the purification step. Various strategies
to address this issue, including low temperature culture, eukaryotic expression
systems, and chaperone coexpression,
have resulted in success for a limited
number of domains. We also observed
some instances of substantial improvement using different domain boundaries,
suggesting a contribution to structural
stability.
To reduce assay complexity and sample consumption, it may be possible to
reduce the number of domains in SH2
profiling based on their overlapping specificity. The known 120 SH2 domains can
be classified into about 30 subfamilies
according to domain amino acid sequence
(e.g., Grb2 family: Grb2, Grap, and
Gads).29 Comprehensive SH2 domain
studies indicated proteins belonging to a
family generally have similar binding
preference,26,30,36 although the possibility
remains that subtle differences in specificity observed in vitro can affect ligand
selection in vivo, such as in the case of
SHP-1 and SHP-2.41,42

Applications of SH2 Profiling in
Cancer Research
SH2 profiling has become a versatile
tool for various levels of cancer studies,

from the detailed analysis of single proteins to broad screening in translational
research.25-27,40,43-46 First, a tyrosine site
on a protein of interest can be readily
characterized by rosette assay using synthesized peptides. For example, it is well
established that phosphorylation of
Y221 of the SH2-SH3 adaptor Crk
by the Abl kinase results in an inhibitory
conformation via an intermolecular
interaction between the Crk SH2
domain and this phosphorylated residue.
Recently, another phosphorylation site
in Crk (pY251) was found in several
human cancer cell lines.46 To explore the
biological function of pY251, a rosette
screen was performed against a SH2
library. Several SH2 domains, including
Abl SH2, were found to bind this site,
and this was confirmed by pull-down
and surface plasmon resonance (SPR)
experiments. The Crk pY251 was then
shown to regulate activation of Abl
in vitro and in vivo. Interestingly, the
binding of Abl SH2 and pY251 was relatively weak, consistent with the fact that
the sequence surrounding Y251 does not
match the reported Abl SH2 domain
consensus, suggesting the interaction
between Crk and Abl is dynamic.
Similarly, previously uncharacterized
carboxy-terminal tyrosine phosphorylation sites in Vav1 were screened by the
rosette assay, leading to the hypothesis
that Vav1Y826 and Csk are involved in
the autoinhibition of NFAT.45 Along
with identifying candidate binding
proteins, rosette can provide apparent
dissociation constants for tyrosine phosphorylated peptides by SH2 binding
curve fitting.43
Second, SH2 profiling has been
applied to cultured cell samples, providing the tyrosine phosphorylation signature of samples based on the presence of
SH2 binding sites. We showed distinctive SH2 binding patterns in response to
cell adhesion and growth factor stimulation, as well as in cells expressing different oncogenic PTKs.25-27 Notably, SH2
profiles sometimes can discern a subtle
change of tyrosine phosphoproteomes.
For example, ectopic expression of
oncogenic Src into a mouse fibroblast
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cell line lacking c-Src, Yes, and Fyn
kinases induces pre-invadopodia formation.44 Interestingly, the more invasive
phenotype capable of matrix degradation at invadopodia sites requires coexpression of wild-type c-Src. In this case,
the global tyrosine phosphorylation levels of both cell lines are equivalent due
to the dominant effect of v-Src. However, a rosette assay detected enhanced
binding of SH2 domains, including Abl,
Crk, and Nck, which are known to interact with cortactin, suggesting they play a
role in the cortactin-mediated invadopodia maturation.44
In addition to focused basic research
studies, application of SH2 profiling to
more complex samples such as a set of
human cancer cell lines is important to
evaluate assay performance and validate
it as a diagnostic tool. To this end, we
examined various lung cancer cell lines
with different genetic backgrounds such
as EGFR and KRAS mutations.40 The
SH2 profiles of cell lines were compared
using a hierarchical clustering analysis
for rosette and far-Western data. The
resulting clusters from both assays were
overall similar and correlated not only
with RTK status (EGFR and MET activity) but also RAS mutation status. For
example, one cluster was enriched in
cells with high EGFR and MET activity,
whereas another cluster contained cells
with mutant RAS and low EGFR and
MET activity. Interestingly, far-Western–
based clustering clearly separated 2 RAS
mutant groups, one of which contained
an EGF-TKI–sensitive cell line. Since
KRAS mutation is known a predictor of
EGFR-TKI resistance with rare exception (i.e., KRAS mutant and TKI-sensitive),47,48 it will be intriguing to determine
if SH2 profiling can predict these rare
cases. Furthermore, assessment of individual probes revealed that a group of
SH2 domains bound more strongly to
cells with higher sensitivity to EGFR
inhibitor (erlotinib), suggesting they may
serve as predictive biomarkers for TKI
treatment. Taken together, this study
illustrates the potential of SH2 profiling
to classify cancer cells from the same

tumor type independent of oncogene
mutation status, protein expression, or
marker status information.
Because tumor cell lines do not necessarily recapitulate the signaling state
of cancer cells in vivo, we also applied
SH2 profiling to patient samples. Using
the quantitative 1-tube OTM assay, we
analyzed leukemia patient samples (10
acute myeloid leukemia [AML] and 5
CML) in comparison with healthy donor
controls.27 A clustering analysis demonstrated correlation between the type of
disease or treatment and SH2 binding:
One cluster consisted of half of the AML
samples and presented strong overall
SH2 binding, the rest of AML and
untreated CML samples were coclustered, and a cluster of treated CML
and normal controls with weak signal
was also clearly separated. By ranking
the relative levels of SH2 binding for
each leukemia sample, distinct SH2
preferences for different diagnostic
classes became apparent, such as the
specificity of the GAP SH2 domain
toward untreated CML. These data suggested that OTM profiling could be used
to distinguish different types of leukemia. Currently, a rosette screen using a
larger number of CML and CLL samples
is under way.
For many of the solid tumors investigated so far, we observed relatively
weak levels of phosphotyrosine signal in
all SH2 analytical platforms. As a result,
some of the subtle but biologically
important information may be missed if
these differences are too small to be distinguished. Since OTM and rosette
assays provide only a single data point
for a SH2 domain and a sample, they are
particularly affected by low signal and
higher noise levels. To discern more
subtle differences in the SH2 binding
pattern, we performed SH2 profiling of
tumor tissues using quantitative farWestern blotting (Figs. 2 and 3). In
accordance to our findings in different
cancer cell lines, we observed substantial differences in the phosphotyrosine
profiles between colon cancer and breast
cancer samples, as well as within each
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tumor type. Based on hierarchical cluster analysis, colon and breast cancer
samples were grouped in 7 and 4 major
clusters, respectively. To gain deeper
insights into the biological relevance of
the different clusters, we related the
clusters to the pathological stage of disease. For colon cancer, no significant
correlation was observed between the 7
major clusters and the different stages of
disease. In addition, as far as data were
available, no overall correlation was
found between SH2 profiles and the
mutational status of the KRAS gene
(Fig. 2). In contrast, breast cancer samples from advanced stages of disease
were significantly overrepresented in 2
of the 4 major clusters (Fig. 3, clusters c
and d, respectively; P < 0.001).
In an attempt to assign the differences
in phosphoactivity depicted by SH2 profiling to tyrosine kinase activity, we
determined the protein expression levels
of MET and members of the ErbB-family
frequently altered or overexpressed in
colon and breast cancer, respectively.
Strikingly, a high level of MET expression was significantly correlated with 3
closely related colon cancer clusters (Fig.
2, clusters d, e, and f, respectively; P <
0.001). In breast cancer, increased levels
of ErbB2 and ErbB3 expression were significantly overrepresented in the 2 clusters (c and d, respectively; P < 0.001),
concurrently correlating with advanced
stages of disease. Taken together, our
data demonstrate that SH2 profiling of
clinical samples may provide a rich
source of important and potentially predictive information about cancer cell signaling and patient outcomes.

Challenges
Our collective efforts in the past decade
have validated the original concept of
SH2 profiling: A set of SH2 domains can
serve as a means to profile the global tyrosine phosphorylation state. We showed
SH2 profiling is a powerful tool to predict
biological partners for a specific tyrosine
motif on a protein and to classify cancer
cells. The 3 analytical platforms are
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Figure 2. SH2 profiling of colon cancer. Tumors samples (n = 57) were snap frozen immediately
after surgical removal and whole cellular extracts were prepared as previously described.25 FarWestern blot analysis was performed with 20 µg of lysate per sample. Lysates were separated
on 4% to 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gradient
gels, transferred to PDVF membranes, and probed with biotinylated SH2 domains. Streptavidin–
horseradish peroxidase (HRP) conjugate was used for detection. Images were scanned and
analyzed by the ImageJ software (National Institutes of Health, Bethesda, MD), and digitalized
profiles were segmented into bins as previously described.40 Subsequently, correlative,
unsupervised hierarchical cluster analysis was performed using the MeV software (version 4.6;
MeV, Boston, MA). The 7 major clusters (a-f) identified by cluster analysis are shaded in gray. Levels
of MET expression, determined by Western blot analysis, were categorized as moderate or strong;
lack of MET expression was categorized as absent. The genomic status of codons 12 and 13,
respectively, of the human Kras gene was determined by restriction fragment length polymorphism
(RFLP) analysis as previously described.40 Pathological staging is given in accordance with the
2010 American Joint Committee on Cancer classification.

versatile in that rosette assay serves as a
rapid SH2 library screening tool, quantitative far-Western analysis provides a functional signature of the tyrosine
phosphoproteome, and OTM offers a sensitive 1-tube competitive binding assay.
We recognize, however, technical hurdles
and challenges exist for the application of
SH2 profiling to translational cancer
research. Clinical specimens are usually
limited in quantity and availability. Considering the future diagnostic application,

it is ideal that all analyses be carried out
with the amount of tissue provided by a
needle biopsy (~10 mg tissue).49 For cultured cell samples, SH2 profiling is sensitive enough without phosphoprotein
enrichment, thereby requiring a smaller
amount of sample than for MS-based
phosphoproteomics. In the case of solid
tumor specimens, however, we sometimes observe a significantly lower signal
level than with cultured cells, increasing
sample requirement. Low signal-to-noise

levels affect data quality, particularly for
the rosette and OTM screening platforms.
In these systems, one SH2 probe gives
only one data value as the binding assay is
performed within a sample dot. To detect
subtle differences in SH2 binding between
tumor samples, sufficient signal intensity
is necessary. As a result, quantitative
phosphotyrosine profiles may not fully be
captured by the OTM and rosette assay.
On the other hand, quantitative far-Western, which requires 15 to 50 µg per SH2
domain probe, can reveal distinct SH2
binding patterns, and thus tumor-specific
clusters are visible (Figs. 2 and 3). This
dilemma between sample requirement
and data quality is currently a hurdle for
implementation of SH2 profiling to largescale tumor analysis. Nevertheless, the
observation that 5 selected SH2 domains
were sufficient to provide distinct clusters
relevant to breast cancer stages (Fig. 3)
suggests that the use of rosette/OTM to
exclude domains with low signal prior to
far-Western could minimize sample
consumption.
Low phosphotyrosine signals can in
part be attributed to heterogeneity and
impurity of cancer tissue specimens,
which contain various amounts of normal
cells and connective tissues. This is consistent with the fact that purified hematopoietic cells usually show better quality
data, and disease-relevant SH2 profiles
have been obtained using the OTM
assay.27 In addition, in a preliminary
rosette screening, we observed that
HER2/ErbB2-positive tumors were coclustered by their strong binding to
known SH2 domains downstream of
HER2/ErbB2. Thus, we assume OTM/
rosette SH2 platforms should be capable
of differentiating tumors containing a
higher percentage of cancer cells and/or
driven by TK oncogenes. We note, however, that some normal cells such as
immune cells associated with inflammatory tumors can contribute to the malignant phenotype of cancer.7

Perspectives
Toward personalized molecular diagnosis
using SH2 profiling, we are attempting to
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Figure 3. SH2 profiling of native breast cancer samples. Profiling of tumor samples (n = 34) and
processing of profiles were performed as described in Fig. 2. The 4 major clusters (a-d) determined
by correlative, unsupervised clustering are shaded in gray. Normal breast tissue (N) served as a
control. Protein expression levels of ErbB2, ErbB3, and ErbB4 were determined by Western blot
analysis.

assign different SH2-based clusters to
clinically relevant parameters associated
with cancer development, progression,
and effective therapeutic intervention.50
As suggested by our data on lung cancer
cell lines and native breast cancer samples, SH2 profiling may be of particular
value for improved classification of
tumors and stratification of patients in
combination with established clinical
and pathological parameters. Establishing this would require well-controlled
retrospective or prospective studies of
cancer patients treated with different drug
combinations, including tyrosine kinase
inhibitors, to demonstrate that therapeutic

benefits and improvements in the clinical
course of disease can be predicted by
SH2 profiling. However, it may be naive
to assume phosphotyrosine profiles
detected by a single modular domain
family can be an independent prognostic
marker for human cancer, a complex
genetic disease. To fully decipher aberrant signaling in cancer in detail with the
aim of identifying specific therapeutic
targets, additional information beyond
the mere SH2 profile may be needed.
We assume TK signaling status as a
whole may predict patient outcome, particularly in a subset of tumors where TK
signaling drives oncogenesis. How can
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this comprehensive view of TK signaling
status be captured? As tyrosine kinases
and phosphatase are the key players controlling the cellular state of phosphorylation, comprehensive profiling of kinase/
phosphatase expression may be one
promising approach to guide the interpretation and classification of SH2 profiles,
as exemplified above for the kinases
MET and ErbB in colon and breast cancer. For instance, expression data of particular kinases, phosphatases, and SH2/
PTB proteins will be useful in specifying
the pTyr-dependent protein interactions
that actually occur in cells. SH2 profiling
(using purified SH2 domains) detects the
presence of binding sites for SH2
domain–containing proteins regardless of
their expression in cell, whereas gene or
protein expression indicates the protein is
actually available to mediate signaling.
Expression data can also help in the efficient design of SH2 profiling assays
through the exclusion of unexpressed
SH2 proteins.
Knowledge of the genomic status and
activity of kinases and phosphatases will
also without doubt provide important
information for the classification of SH2
profiles. Correlations between SH2 profiles and somatic mutation in kinase/
phosphatase genes are informative to
specify activated TK signaling networks.
Furthermore, combining SH2 profiling
with other phosphoproteomics tools may
also turn out to be a powerful combinatorial strategy. Detailed characterization of
tyrosine phosphorylated proteins by MS
after pull-down of phosphoproteins with
informative SH2 domains should have
great potential, enabling the identification of executors and substrates of tyrosine phosphorylation, which may serve as
potential targets for the development of
rational therapies.

Conclusion
As demonstrated for many different
tumor cell lines and native tumor samples, SH2 profiling is a powerful technique for deciphering and classifying
aberrant phosphotyrosine-dependent signaling in cancer. Given its sensitivity and
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relatively small sample requirement, SH2
profiling may be of extraordinary value
for the analysis of tumor tissues and monitoring of tumors during therapy where
only limited amounts of cancer cells are
present. It may also provide “geographical” profiles of the tyrosine phosphorylation state in different areas of the tumor,
addressing the important issue of tumor
heterogeneity and diversity of signaling.
SH2 profiling, in combination with other
phosphoproteomics tools and informatics, is evolving as a simple, robust, and
highly sensitive technique with both
research and clinical applications.
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